8-Chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine;methanesulfonic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-Chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine;methanesulfonic acid
• 英文别名: 8-chloro-9-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]purin-2-amine;methanesulfonic acid
• 化学式: C15H19ClN6O4S
• 分子量: 414.9
• InChiKey: WFMOLULQARQWTB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.63
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  155
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• COMBINATION THERAPY
  申请人：Novartis AG

  公开号：EP2916841A1

  公开（公告）日：2015-09-16
• [EN] COMBINATION THERAPY<br/>[FR] POLYTHÉRAPIE
  申请人：NOVARTIS AG

  公开号：WO2014074580A1

  公开（公告）日：2014-05-15

  A pharmaceutical combination comprising (a) a compound of formula (I), [Chemical formula should be inserted here as it appears on Abstract in paper form] or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering from a proliferative disease; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.